EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

The role of venoactive compounds in the treatment of chronic venous disease

Monika Lecomte Gloviczki, Stavros K Kakkos, Tomasz Urbanek, John Chuback, Andrew Nicolaides

Journal of Vascular Surgery: Venous and Lymphatic Disorders · 2025

DOI: 10.1016/j.jvsv.2025.102258 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Journal of Vascular Surgery: Venous and Lymphatic Disorders, 2025. Verfasst von Monika Lecomte Gloviczki und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine and Gonda Vascular Center, Mayo Clinic, Rochester, MN; Vascular Science & Art, LLC, Scottsdale, AZ. Electronic addres…. Hauptthemen laut MEDLINE: Venous Insufficiency, Veins, Varicose Ulcer, Cardiovascular Agents. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Chronic venous disease (CVD) is a major global health issue, affecting millions of people and contributing to significant morbidity and economic strain. The condition's pathophysiology is complex, involving both mechanical and biochemical processes that lead to venous reflux, obstruction, and chronic inflammation. This review focuses on the role of venoactive compounds (VACs), also known as venoactive drugs in Europe and other parts of the world, in managing CVD. The aim was to review the scientific evidence and to define the role of VACs within the comprehensive treatment algorithm for CVD, alongside established and well adopted interventional therapies and noninterventional therapies such as compression. METHODS: The review of the scientific evidence was done on VACs mechanism of action and efficacy in alleviating CVD symptoms, reducing swelling or venous edema, and improving healing of venous leg ulcers. Whenever available, systematic reviews, meta-analyses and randomized controlled trials were used. The quality of evidence assessment followed the GRADE methodology from A (high), B (moderate), to C (low to very low) quality. RESULTS: Venoactive drugs or compounds share similar effects, such as sealing the endothelial barrier, enhancing lymphatic drainage, reducing edema, improving venous tone, inhibiting leukocyte adhesion to vein walls/valves and inflammatory mediator release, lowering blood viscosity, and promoting red blood cell flexibility. Scientific evidence on the VACs effectiveness on CVD symptoms (pain, cramps, and heaviness) and swelling or edema have shown some variability. Micronized purified flavonoid fraction (MPFF) and Ruscus extract combined with hesperidin methyl chalcone and ascorbic acid had the highest, mostly level A, quality of evidence. In venous leg ulcers, micronized purified flavonoid fraction, sulodexide, and pentoxifylline were the most effective adjunctive treatments, with evidence level A. CONCLUSIONS: The existing scientific evidence provides a strong rationale for incorporating VACs into a comprehensive treatment plan for CVD, alongside established interventional therapies and noninterventional approaches like compression, to optimize patient outcomes and improve quality of life.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Venous InsufficiencyVeinsVaricose UlcerCardiovascular AgentsHumansChronic DiseaseTreatment OutcomeWound Healing

Stichwörter der Autor:innen

Calcium dobesilateChronic venous diseaseDiosminHidrosminHorse chestnut seed extractHydroxyethylrutosidesMicronized purified flavonoid fractionPentoxifyllineRed vine leaf extractRuscus extractSulodexideVenoactive compounds or drugsVenous edemaVenous leg ulcersVenous symptoms

Substanzen

Cardiovascular Agents

Autor:innen und Institutionen

  • Department of Internal Medicine and Gonda Vascular Center, Mayo Clinic, Rochester, MN; Vascular Science & Art, LLC, Scottsdale, AZ. Electronic address: gloviczki.monika@gmail.com.
  • Department of Vascular Surgery, University of Patras Medical School, Patras, Greece.
  • Department of General Surgery, Vascular Surgery, Angiology and Phlebology, Medical University of Silesia, Katowice, Poland.
  • Chuback Vein Center, Paramus, NJ.
  • Vascular Screening and Diagnostic Centre, Nicosia, Cyprus; Imperial College, London, UK; University of Nicosia Medical School, Nicosia, Cyprus.

Zitieren

APA

Gloviczki, M. L., Kakkos, S. K., Urbanek, T., Chuback, J., & Nicolaides, A. (2025). The role of venoactive compounds in the treatment of chronic venous disease. Journal of Vascular Surgery: Venous and Lymphatic Disorders. https://doi.org/10.1016/j.jvsv.2025.102258

Vancouver

Gloviczki ML, Kakkos SK, Urbanek T, Chuback J, Nicolaides A. The role of venoactive compounds in the treatment of chronic venous disease. Journal of Vascular Surgery: Venous and Lymphatic Disorders. 2025. doi:10.1016/j.jvsv.2025.102258

BibTeX
@article{Gloviczki2025,
  author = {Gloviczki, Monika Lecomte and Kakkos, Stavros K and Urbanek, Tomasz and Chuback, John and Nicolaides, Andrew},
  title = {The role of venoactive compounds in the treatment of chronic venous disease},
  journal = {Journal of Vascular Surgery: Venous and Lymphatic Disorders},
  year = {2025},
  doi = {10.1016/j.jvsv.2025.102258}
}
Kostenlos starten →